Skip to main content

Advertisement

SpringerLink
Log in

Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma.

Methods

Patients received i.v./intrahepatic cisplatin, i.v. gemcitabine, and i.v. treosulfan (CGT) on day 1 and 8 as first-line (n = 1), second-line (n = 9), third-line (n = 1) or fourth-line (n = 1) therapy. Cisplatin, gemcitabine, and treosulfan (CGT)-therapy was repeated every 5 weeks until progression of disease occurred. A maximum of six CGT-cycles (mean, 2 cycles) was administered per patient.

Results

No objective response was observed, six patients (50%) had stable disease and six (50%) patients progressed upon first reevaluation. Overall survival of all the 12 patients was 6 months. Patients with stable disease reached a median overall survival of 12 months, while patients with disease progression upon first reevaluation had a median overall survival of 4 months, only. Grade III/IV related hematotological side effects were experienced in six (leukopenia) and four (thrombocytopenia) patients.

Conclusions

Treatment with CGT may lead to disease stabilization and prolonged survival in a substantial proportion of progressive stage IV uveal melanoma patients, even following heavy chemotherapy treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK (1998) Metastatic melanoma from intraocular primary tumors: the southwest oncology group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 21(6):568–572

    Article  PubMed  CAS  Google Scholar 

  2. Bedikian AY, Legha SS, Mavligit G et al (1995) Treatment of uveal melanoma metastatic to the liver. Cancer 76(9):1665–1670

    Article  PubMed  CAS  Google Scholar 

  3. Collaborative Ocular Melanoma Study Group (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (COMS): COMS report no. 15. Arch Ophthalmol 119(5):670–676

    Google Scholar 

  4. Becker JC, Terheyden P, Kämpgen E et al (2002) Treatment of disseminated ocular melanoma with sequential fotemustine, interpheron alpha, and interleukin 2. Br J Cancer 87(8):840–845

    Article  PubMed  CAS  Google Scholar 

  5. Kivelä T, Suciu S, Hansson J et al (2002) Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 39(8):1115–1120

    Article  Google Scholar 

  6. Mavligit GM, Charnsangavej C, Carrasco CH et al (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260(7):974–976

    Article  PubMed  CAS  Google Scholar 

  7. Leyvraz S, Spataro V, Bauer J et al (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15(7):2589–2595

    PubMed  CAS  Google Scholar 

  8. Neale MH, Myatt NE, Khoury GG et al (2001) Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 11(6):601–609

    Article  PubMed  CAS  Google Scholar 

  9. Iwasaki H, Huang P, Keating MJ, Plunkett W (1997) Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90(1):270–278

    PubMed  CAS  Google Scholar 

  10. Schmittel A, Schmidt-Hieber M, Martus P et al (2006) A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 17(12):1826–1829

    Article  PubMed  CAS  Google Scholar 

  11. Schmittel A, Scheulen ME, Bechrakis NE et al (2005) Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 15(3):205–207

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Jens Atzpodien has been supported by grants of the Deutsche Krebshilfe, Wilhelm Sander-Stiftung, and Deutsche Gesellschaft zur Förderung immunologischer Krebstherapien e.V.

Conflicts of interest:

All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) this work.

Author information

Authors and Affiliations

  1. Fachklinik Hornheide an der Westfälischen Wilhelms-Universität Münster, Dorbaumstr. 300, 48157, Münster, Germany

    Jens Atzpodien, Kerstin Terfloth & Michael Fluck

  2. Europäisches Institut für Tumor Immunologie und Prävention (EUTIP), Mühlenpfad 5, Bad Honnef, Germany

    Jens Atzpodien & Martina Reitz

Authors
  1. Jens Atzpodien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerstin Terfloth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Fluck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martina Reitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens Atzpodien.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atzpodien, J., Terfloth, K., Fluck, M. et al. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol 62, 685–688 (2008). https://doi.org/10.1007/s00280-007-0655-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0655-9

Keywords

Search

Navigation